Intellia Therapeutics CRISPR Breakthrough: Pivotal Success
Intellia Therapeutics Achieves Landmark Success in In Vivo CRISPR Gene Editing Trial for Hereditary Angioedema In a move that could redefine the future of genomic medicine, Intellia Therapeutics has announced that its groundbreaking in vivo CRISPR gene editing therapy has successfully met its primary endpoint in a pivotal Phase 3 clinical trial. The trial focused … Read more